Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes.
Publication/Presentation Date
5-1-2022
Abstract
BACKGROUND: Weight changes during neoadjuvant chemotherapy (NAC) for pancreatic cancer (PDAC) are not well studied. We hypothesized that weight loss may predict poor outcomes.
METHODS: Weight change from NAC initiation to pancreatectomy was grouped: gain (≥5%), stable, and loss (≥5%). Pathologic, postoperative, and survival outcomes were compared.
RESULTS: 95 patients were included: 31.6% lost weight, 58.9% maintained weight, and 9.5% gained weight. There were no differences in chemotherapeutic regimens. Median recurrence-free survival (RFS) and overall survival (OS) were similar between patients with stable weight and those who lost weight (RFS: 9.6vs14.0months; OS: 25.8vs26.7months). Among those who gained weight, RFS (29.5months) and OS (38.4months) were greater relative to the other weight categories. On multivariable regression, weight gain was associated with improved RFS compared to loss (HR = 0.16).
CONCLUSION: Most patients maintain or lose weight during NAC, and weight loss does not predict poor outcomes. Weight gain may predict improved RFS.
Volume
223
Issue
5
First Page
927
Last Page
932
ISSN
1879-1883
Published In/Presented At
Hue, J. J., Markt, S. C., Sugumar, K., Kyasaram, R. K., Shanahan, J., Rothermel, L. D., Ammori, J. B., Hardacre, J. M., Winter, J. M., & Ocuin, L. M. (2022). Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. American journal of surgery, 223(5), 927–932. https://doi.org/10.1016/j.amjsurg.2021.10.001
Disciplines
Medicine and Health Sciences
PubMedID
34642044
Department(s)
Department of Surgery, Lehigh Valley Topper Cancer Institute
Document Type
Article
